SOURCE: BioTech Medics, Inc.

September 26, 2007 10:48 ET

BioTech Medics, Inc. CEO Joins Overstock's Pat Byrne in Stock Shorting War

DALLAS, TX--(Marketwire - September 26, 2007) - BioTech Medics, Inc. (PINKSHEETS: BTME) Chairman and CEO Keith Houser is joining Dr. Pat Byrne's war on stock shorting. "Today," said Keith Houser, "the OTCBB released the September 14 'Short Interest Report.' BTME's share shorting was up 470,150% (no misprint). On September 14 only 16,543 BTME shares traded. BTME stock was shorted by 57%. I believe this figure is grossly understated. While talking to officials at OTCBB, they stated that there are discrepancies in the reports. These discrepancies include: 1) no guarantee of 100% reporting compliance by all brokerage firms, 2) offshore non-member firms are not required to report, and 3) shorting could be significantly higher on non-reporting days to avoid disclosure. This is outrageous! We have seen two specific brokerage firms take the BTME Bid and Ask price down 33% to 50% without any trading. This is clearly a regulatory violation. We have been and are continuing to file Suspicious Trading Reports (SARS) and complaints with the SEC, NASD, NASDAQ and other agencies. Shorting is not illegal, but brokerage firms illegally manipulating the stock without any trades is illegal (for a grey market penny stock) as only client directed trades may be made; market makers are prohibited from manipulation.

In 2006, BTME hired to analyze shorting of BTME over the previous year. reported a total of 8,351,702 shares shorted. Based upon their study the Squeeze Trigger price of $.02 would start a potential squeeze on the short sellers. Typically, the last Friday of each trading month is the end of the monthly short selling contract. This coming Friday, September 28 will be that day. "I encourage any BTME shareholder who is angered over those who are harming the company by personally profiting from shorting this stock to take a stand against the shorting," said Mr. Houser.

BTME is a 21st century alternative medicine company. BTME operates and affiliates with 4 Pain Management & Wellness Centers in the USA and several pending offshore. BTME has exclusive and proprietary high powered FDA cleared therapeutic medical lasers for the reduction and/or elimination of muscular, skeletal and/or arthritic pain without drugs or surgery. BTME also owns 4 US Letters of Patent for SHBAN Solution, a non-toxic antimicrobial, which has been clinically proven to kill the Avian Bird Flu Virus as well as 99% of most germs, viruses and molds without harmful bleach or ammonia. SHBAN is currently being sold in a 3 oz Go Anywhere Hand Sanitizer Mist. The superiority of SHBAN is that it is long-lasting for hours (as SHBAN does not contain alcohol), does not stain and has no odor.

Safe Harbor for Forward-Looking Statements.

This article may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results may vary.

Contact Information

  • Contact:
    BioTech Medics, Inc.
    Investor Relations